Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

被引：18
|
作者：
Lachowiez, Curtis
Konopleva, Marina
Kadia, Tapan M.
Daver, Naval
Loghavi, Sanam
Wang, Sa A.
Adeoti, Maria
Pierce, Sherry A.
Takahashi, Koichi
Short, Nicholas J.
Sasaki, Koji
Borthakur, Gautam
Issa, Ghayas C.
Wierda, William G.
Pemmaraju, Naveen
Bravo, Guillermo Montalban
Ferrajoli, Alessandra
Jain, Nitin
Masarova, Lucia
Yilmaz, Musa
Jabbour, Elias
Garcia-Manero, Guillermo
Kornblau, Steven M.
Ravandi, Farhad
Kantarjian, Hagop M.
Dinardo, Courtney D.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
    Aboudalle, Iman
    Konopleva, Marina Y.
    Kadia, Tapan M.
    Naqvi, Kiran
    Vaughan, Kenneth
    Kurt, Mehmet
    Cavazos, Antonio
    Pierce, Sherry A.
    Takahashi, Koichi
    Masarova, Lucia
    Yilmaz, Musa E.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Kornblau, Steven M.
    Ravandi, Farhad
    Cortes, Jorge
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    BLOOD, 2019, 134
  • [2] Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit, Relapsed/Refractory AML Patients: Interim Results of a Phase 1b/2 Dose Escalation and Expansion Study
    DiNardo, Courtney D.
    Albitar, Maher
    Kadia, Tapan M.
    Naqvi, Kiran
    Vaughan, Kenneth
    Cavazos, Antonio
    Pierce, Sherry A.
    Takahashi, Koichi
    Kornblau, Steven M.
    Ravandi, Farhad
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD, 2018, 132
  • [3] Safety and Efficacy of FLAG-Ida Combined with Venetoclax Treatment for Newly Diagnosed and Relapsed / Refractory AML Patients- a Systematic Review
    Sherban, Adi
    Fredman, Danielle
    Shimony, Shai
    Yeshurun, Moshe
    Raanani, Pia
    Stahl, Maximilian F.
    Gafter-Gvili, Anat
    Wolach, Ofir
    BLOOD, 2022, 140 : 11716 - 11717
  • [4] Venetoclax (VEN) Plus Intensive Chemotherapy (IC) with FLAG-IDA in Patients (Pts) with Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Abaza, Yasmin
    Khan, Talha
    Dinner, Shira
    Frankfurt, Olga
    Altman, Jessica K.
    BLOOD, 2022, 140 : 9036 - 9037
  • [5] Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML - A systematic review
    Sherban, A.
    Fredman, D.
    Shimony, S.
    Yeshurun, M.
    Raanani, P.
    Stahl, M.
    Gafter-Gvili, A.
    Wolach, O.
    LEUKEMIA RESEARCH, 2023, 133
  • [6] Safety and Efficacy of FLAG-IDA-Based Therapy Combined With Venetoclax for the Treatment of Newly Diagnosed and Relapsed/Refractory Patients With AML: A Systematic Review
    Sherban, Adi
    Fredman, Danielle
    Shimony, Shai
    Yeshurun, Moshe
    Raanani, Pia
    Stahl, Maximillian
    Gafter-Gvili, Anat
    Wolach, Ofir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S264 - S264
  • [7] OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
    Ravandi, Farhad
    Carraway, Hetty E.
    Taningco, Lilia
    Dilley, Kimberley
    Laille, Eric
    Gong, Jing
    de Menezes, Daniel Lopes
    Wei, Andrew H.
    BLOOD, 2021, 138
  • [8] Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML
    Wilde, Lindsay
    Martinez-Outschoorn, Ubaldo
    Palmisiano, Neil
    Keiffer, Gina
    Kasner, Margaret
    BLOOD, 2020, 136
  • [9] Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML
    Pratz, Keith W.
    Cherry, Mohamad
    Altman, Jessica K.
    Cooper, Brenda W.
    Podoltsev, Nikolai A.
    Cruz, Jose Carlos
    Lin, Tara L.
    Schiller, Gary J.
    Jurcic, Joseph G.
    Asch, Adam
    Wu, Ruishan
    Hill, Jason E.
    Gill, Stanley C.
    James, Angela J.
    Rich, Elizabeth Shima
    Hasabou, Nahla
    Perl, Alexander E.
    Levis, Mark J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (26) : 4236 - +
  • [10] Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML
    Daver, Naval
    Pollyea, Daniel A.
    Yee, Karen W. L.
    Fenaux, Pierre
    Brandwein, Joseph M.
    Vey, Norbert
    Martinelli, Giovanni
    Kelly, Kevin R.
    Roboz, Gail J.
    Garcia, Jacqueline S.
    Pigneux, Arnaud
    Kshirsagar, Smita
    Dail, Monique
    Wang, Jue
    Mobasher, Mehrdad
    Chen, Lin-Chi
    Hong, Wan-Jen
    Konopleva, Marina
    Andreeff, Michael
    BLOOD, 2017, 130
12345